title: PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease.
abstract: OBJECTIVE
  PET/CT with (18)F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT.
  
  
  CONCLUSIONS
  Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.
authors: Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA. kzukotynski@partners.org
authors: Katherine
authors: K
authors: Zukotynski
authors: Aaron
authors: A
authors: Lewis
authors: Kevin
authors: K
authors: O'Regan
authors: Heather
authors: H
authors: Jacene
authors: Christopher
authors: C
authors: Sakellis
authors: Samuel
authors: S
authors: Almodovar
authors: David
authors: D
authors: Israel
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D007938:Leukemia / Q000000981:diagnostic imaging* / Q000473:pathology*; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology*; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18